PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting ...
Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in 2026 and beyond PISCATAWAY, N.J., Jan. 29, 2026 /PRNewswire/ -- GenScript Biotech ...
In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...
(Reuters) -The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national intelligence, renewing its concerns about GenScript Biotechnology's ...
PISCATAWAY, N.J., July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG ...
PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...
GenScript is best known for its gene synthesis capabilities, which we estimate is more than half of the life science services and products segment. In 2014, GenScript was the leader in gene synthesis, ...
GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction. Legend Biotech continues to invest in R&D to expand the ...
GenScript currently has good financial health, with just USD 46 million of debt in 2020 and USD 629 million of cash. We think this provides it enough cash to spend over USD 500 million for research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results